A patient at the University of Maryland received a genetically modified pig heart. The surgery worked. Then an infectious disease crossed the species barrier. That case didn't end xenotransplantation research, but it should have ended any claim that the biological risks are under control.
On March 24, 2026, the Vatican's Pontifical Academy for Life released a 90-page ethical framework on xenotransplantation, the most detailed institutional review the field has received. The document endorses pig organ transplants as ethically permissible. It also concedes, plainly, that the infection risk is "not fully quantifiable." That phrase is doing a lot of work. After 3 decades of research, Harvard Medical School's Jay Fishman, one of the world's foremost experts on infectious risks from genetically modified pigs, contributed to that framework. If Fishman cannot put a number on the risk, the field cannot put a number on the risk.
There are currently 3 active clinical trials in the United States: 2 for kidneys, 1 for liver. The first FDA-approved xenokidney trial launched in 2025. The 2022 pig heart recipient survived roughly 2 months. Pig kidney transplants have shown what researchers call "relative success," which is a phrase that belongs in a progress note, not a headline.
The Infection Problem Has No Clean Answer Yet
The specific risk is xenozoonosis: pathogens crossing from pig to human, potentially into a human host whose immune system is already suppressed to prevent organ rejection. The Vatican document puts it directly: the risk exists, is documented, but "its true magnitude cannot be precisely calculated." Genetic engineering has reduced some known transmission vectors. It has not eliminated unknown ones. Porcine endogenous retroviruses, embedded in pig DNA, cannot be fully edited out, and their behavior in long-term human hosts is not established by any current trial.
The counterargument deserves fair treatment: roughly 100,000 Americans are currently on the organ transplant waiting list, and about 20 people die each day waiting. If a pig kidney extends a life by years, the expected value calculation may favor the risk. That point is genuinely correct for the individual patient. It does not answer the public health question, which is what happens if a novel pathogen escapes containment and reaches an immunocompetent population.
Those are two separate risk frameworks, and the field keeps treating them as one.
What the Numbers Require
The Vatican framework asks doctors to disclose "the probability of rejection" as part of informed consent. That's standard. What the framework does not demand, and what the FDA trials should require, is mandatory public reporting on every infectious event, including those that do not meet the threshold for a serious adverse event under current definitions. Surveillance gaps are where novel pathogens historically disappear from the record until they don't.
The field also needs to stop treating psychological harm as a secondary concern. Recipients may experience identity disruption from carrying a genetically modified animal organ. That is a real outcome requiring real support infrastructure, not a footnote in a 90-page ethics document.
Genetic engineering has made pig organs biologically closer to compatible. The immune rejection data is genuinely improving. But "improving" and "solved" are different claims at different points on a timeline, and right now the timeline for long-term safety data is measured in months, not years.
The Maryland case wasn't an anomaly to dismiss. It was a data point to build from. The trials should continue, under the strictest possible surveillance requirements, with full public reporting. The patients who volunteered for those trials deserve both the chance and the honesty about what remains unknown.
